Joann Mahan, APRN
Family · Fort Smith, ARNPI 1104225317
Payments from drug & device makers
Across 154 payments — averaging $31.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Biohaven Pharmaceuticals, Inc.$384
- AbbVie$290
- Collegium Pharmaceutical, Inc.$285
- GRT US Holding, Inc.$280
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$233
- plus $1K from 24 others
What the payments were for
- Travel & lodging$1,37528%
- Food & beverage$3,45271%
- Education$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 13 | $1,992 |
| Biohaven Pharmaceuticals, Inc. | 9 | $384 |
| AbbVie | 20 | $290 |
| Collegium Pharmaceutical, Inc. | 16 | $285 |
| GRT US Holding, Inc. | 7 | $280 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $233 |
| Paratek Pharmaceuticals, Inc. | 12 | $223 |
| Eisai Inc. | 11 | $222 |
| Teva Pharmaceuticals USA, Inc. | 8 | $180 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $100 |
| Lilly USA, LLC | 5 | $71 |
| Valinor Pharma, LLC | 3 | $60 |
| Sunovion Pharmaceuticals Inc. | 3 | $51 |
| Scilex Pharmaceuticals Inc. | 3 | $50 |
| Avanir Pharmaceuticals, Inc. | 3 | $49 |
| Redhill Biopharma Inc. | 3 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Neurocrine Biosciences, Inc. | 2 | $40 |
| Sun Pharmaceutical Industries Inc. | 2 | $34 |
| Tonix Medicines, Inc. | 2 | $33 |
| Pfizer | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Biodelivery Sciences International, Inc. | 2 | $28 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Vertex | 1 | $22 |
| Johnson & Johnson | 1 | $18 |
| Urovant Sciences Inc | 1 | $17 |
| Averitas Pharma Inc. | 1 | $15 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMEDII$1,582
- NURTEC ODT$299
- Qutenza$229
- Dayvigo$123
How this compares
$4,881 in reported general payments places this provider in the 90th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 2,473 | $72,937 |
| LinzessLinaclotide | 101 | $67,701 |
| Buprenorphine | 161 | $48,754 |
| BelbucaBuprenorphine Hcl | 58 | $45,963 |
| MovantikNaloxegol Oxalate | 98 | $42,591 |
| RelistorMethylnaltrexone Bromide | 18 | $40,737 |
| Naloxone Hcl | 147 | $11,487 |
| Pregabalin | 323 | $7,952 |
| Gabapentin | 614 | $7,369 |
| Diclofenac Sodium | 111 | $5,532 |
| Tizanidine Hcl | 576 | $4,992 |
| Lidocaine | 31 | $4,372 |
| Baclofen | 171 | $2,579 |
| Ondansetron OdtOndansetron | 58 | $2,494 |
| Tramadol Hcl | 242 | $2,030 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $290 | $67,701101 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $285 | $45,96358 claims |
| Redhill Biopharma Inc.Movantik | $44 | $42,59198 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $233 | $40,73718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,103 family providers in Arkansas.
Other family in Fort Smith
- Nina CopelandFort Smith$207K
- Amanda DavisFort Smith$46K
- Scarlett BoneFort Smith$16K
- Nathan WilliamsonFort Smith$15K
- Yong OunpraseuthFort Smith$14K
- Karen WilliamsFort Smith$11K
- Nycole OliverFort Smith$10K
- Bentlee RundellFort Smith$10K
- Nata MatthewsFort Smith$10K
- Emily ChristensenFort Smith$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.